Seven of the 40 patients (18%) who resumed gilteritinib after HSCT experienced AEs that led to dosage reductions (1 each with grade 4 thrombocytopenia and neutropenia, grade 3 hypokalemia, grade 1 peripheral edema and grade 3 weight gain, grade 2 pleural effusion, grade 3/4 increased blood creatine phosphokinase, grade 1 pleural thickening, and grade 2 increased ALT). The gene discussed is GPT; the disease is Decreased total neutrophil count.